#United States #New York #Class Action #Geron Corporation #Rytelo

Recent Developments for Geron Corporation Shareholders

The Gross Law Firm has issued a crucial announcement for shareholders of Geron Corporation (NASDAQ: GERN). If you've purchased shares in GERN during the specified class period from February 28, 2024, to February 25, 2025, it is essential to act promptly and consider joining a class-action lawsuit. This legal initiative puts forth a chance for shareholders to potentially recover losses suffered from the company's misleading disclosures.

Background of the Case

The allegations against Geron Corporation center around the company's statements concerning Rytelo (imetelstat), a drug they promoted as a solution for patients. The defendants purportedly presented optimistic projections for the drug, emphasizing its potential to address significant unmet medical needs while downplaying the challenges posed by mandatory weekly monitoring and competition in the marketplace.

However, February 26, 2025, marked a pivotal moment when Geron revealed its fourth-quarter results for fiscal 2024. The stumbling performance of Rytelo was attributed to several adverse factors: increased competition, seasonal market fluctuations, and a surprising lack of awareness among potential users. This announcement led to a drastic drop in Geron's stock price, plummeting from $2.37 per share to $1.61 in a single day, signaling a 32.07% decline.

Class Action Details

Deadline and Next Steps

The deadline for shareholders to join the class action is set for May 12, 2025. To participate, investors are encouraged to register online. Once registered, shareholders will gain access to portfolio tracking solutions that will keep them informed of the case's progress. Importantly, there’s no cost or obligation for registering, allowing shareholders to engage without financial risks.

Why You Should Care

Engaging in this class action could be significant for numerous shareholders who might not realize they hold claims due to past investments in GERN. This case reflects a broader struggle against corporate malpractice, ensuring that companies are held accountable for any misconceptions they propagate regarding their products and business strategies.

The Gross Law Firm specializes in championing the rights of investors. Their ongoing commitment focuses on seeking restitution for shareholders victimized by deceptive practices that artificially boost stock prices.

Contact Information

For interested shareholders, it’s crucial to act swiftly. Reach out to The Gross Law Firm at their New York office located at 15 West 38th Street, 12th Floor, New York, NY, or via phone at (646) 453-8903. They offer insights and assistance for individuals looking to navigate this legal avenue effectively.

Act now to protect your investments and hold corporations accountable for their actions. The window for participation is closing soon, so don’t miss the chance to stand up for your rights as an investor.